Corcept Therapeutics Corp (CORT) - מקדם חוב לטווח ארוך להון

The Corcept Therapeutics (CORT) market price chart demonstrates the asset's dynamics, with a metric of 0.01. The company's finances are fueled by demand for its Cushing's disease treatment, creating a steady cash flow. The business controls the cortisol regulation niche through unique patents that make switching therapies difficult. Corcept Therapeutics (CORT) is currently expanding its scientific research, adapting its developments to combat cancer and other critical pathologies.

This indicator is calculated as the ratio of accounts payable with a maturity of more than one year to total equity, reflecting the business's degree of dependence on long-term debt financing. The stable cash flow from the sale of endocrine drugs by Corcept Therapeutics (CORT) allows for the effective management of this leverage, which is clearly demonstrated by the ratio of long-term loans to equity.